Drugs / DXP604
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT05381519 | May → Jun 2022 | COVID-19 | Wuhan Institute of Biological Products Co., Ltd | Unknown | Missed primary |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DXP604 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05381519 ↗ |
| Route | Intravenous | “1800mg，IVgtt” NCT05381519 ↗ |